LU, YEN TA,吕衍达,呂衍達,CHANG, CHIA MING,张家鸣,張家鳴,WEI, TSAI YIN,魏采音,魏采音
申请号：
TW105118446
公开号：
TW201704258A
申请日:
2016.06.13
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
The present invention surprisingly found that TLT-1 directly binds to immune cells and triggers cells to express immunosuppressive phenotypes i.e., down-regulation of HLA-DR and up-regulation of PD-L1. The induction of PD-L1 and reduction of HLA-DR by TLT-1 or TLT-1-derived polypeptides can therefore be useful in treating diseases associated with immune hyper-reactivity, such as autoimmune diseases, hypersensitivity reactions, transplantation rejections and graft versus host disorders.本發明驚奇地發現TLT-1直接結合至免疫細胞並觸發細胞以表現免疫抑制表型;即,下調HLA-DR並上調PD-L1。藉由TLT-1或TLT-1衍生之多肽誘導PD-L1並降低HLA-DR可因此用於治療與免疫高反應性相關之疾病,例如自體免疫性疾病、過敏反應、移植排斥及移植物抗宿主病症。
